While there are no immunocompetent MCC mouse models available to investigate whether LSD1i enhances an immune‐response, this is in line with a recent report indicating that LSD1 depletion enhances response to checkpoint inhibitors by activating type 1 interferon signaling, which stimulates T‐cell responses (Sheng et al, 2018). The gene discussed is KDM1A; the disease is Merkel cell skin cancer.